Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

In conclusion, immunogenicity data of biosimilars or biosimilar candidates for TNFα or CD20 inh ibitors were collected in trials that varied in design and procedures for ADAb/nAb detection. In general, immunogenicity parameters of biosimilars are similar to those of their reference products.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research